SeaStar Medical to Present Pediatric Sepsis AKI Data at ASN Kidney Week 2026

  • SeaStar Medical's late-breaking abstract on SAVE Registry data accepted for ASN Kidney Week 2026
  • Presentation focuses on pediatric sepsis-associated AKI outcomes using SCD-PED device
  • Event scheduled for October 22, 2026, in Denver, CO
  • QUELIMMUNE (SCD-PED) is the only FDA-approved treatment for life-threatening pediatric AKI due to sepsis

SeaStar Medical's presentation at ASN Kidney Week 2026 comes as the company seeks to solidify its position in the ultra-rare pediatric AKI market while expanding into adult indications. The FDA's Breakthrough Device Designation for multiple indications suggests regulatory support for SeaStar's technology, potentially accelerating market access. The company's focus on sepsis-related organ failure positions it in a growing area of critical care medicine where treatment options remain limited.

Clinical Validation
Whether SAVE Registry data demonstrates sufficient efficacy to drive adoption of SCD-PED in pediatric sepsis cases
Regulatory Expansion
The pace at which SeaStar Medical can secure additional Breakthrough Device Designations for adult indications
Market Penetration
How NEUTRALIZE-AKI trial results will impact SeaStar's positioning in the adult AKI treatment market